Genmedica Therapeutics is a development-stage biotech that develops a line of compounds with anti-diabetic activity and therapeutics targeting dyslipidemia, obesity, inflammatory and cardiovascular diseases. The company is advancing clinical trials for its candidates and intends to use newly raised funds to complete its product offering. It was founded in 2004 and is led by CEO Alec Mian, Ph.D., with Stephen Donoghue, Ph.D., as VP Clinical Development. The firm is based in Barcelona, Spain. The articles do not disclose current revenues or user metrics. The recent financing is intended to support clinical development and product completion.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2011